JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

VEEV

291.04

+0.02%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

VEEV

291.04

+0.02%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

VEEV

291.04

+0.02%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

VEEV

291.04

+0.02%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

VEEV

291.04

+0.02%↑

Search

Abbott Laboratories

Geschlossen

BrancheGesundheitswesen

126.59 0.73

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

125

Max

126.71

Schlüsselkennzahlen

By Trading Economics

Einkommen

-7.9B

1.3B

Verkäufe

784M

11B

KGV

Branchendurchschnitt

15.631

38.156

EPS

1.26

Dividendenrendite

1.88

Gewinnspanne

12.792

Angestellte

114,000

EBITDA

-465M

2.2B

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+15.54% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

1.88%

2.50%

Nächstes Ergebnis

15. Okt. 2025

Nächste Dividendenausschüttung

15. Aug. 2025

Nächstes Ex-Dividendendatum

14. Okt. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-13B

216B

Vorheriger Eröffnungskurs

125.86

Vorheriger Schlusskurs

126.59

Nachrichtenstimmung

By Acuity

37%

63%

126 / 375 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Abbott Laboratories Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Juli 2025, 12:10 UTC

Ergebnisse

Abbott Labs Pares Outlook, Logs 2Q Profit Gains

16. Apr. 2025, 16:21 UTC

Ergebnisse

Abbott Labs Bracing for Tariffs as Profits Rise -- Update

16. Apr. 2025, 12:14 UTC

Ergebnisse

Abbott Labs 1Q Profit Jumps on Gains in Nutrition, Medical Devices

17. Juli 2025, 13:14 UTC

Ergebnisse

Abbott Labs Stock Falls After Earnings. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17. Juli 2025, 12:16 UTC

Ergebnisse

Abbott Labs Stock Dives After Earnings Miss. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17. Juli 2025, 11:32 UTC

Ergebnisse

Abbott Labs Sees 3Q Adj EPS $1.28-Adj EPS $1.32 >ABT

17. Juli 2025, 11:32 UTC

Ergebnisse

Abbott Labs: See Momentum Carrying Into 2026 >ABT

17. Juli 2025, 11:31 UTC

Ergebnisse

Abbott Labs Sees 2025 Organic Sales Up 7.5%-8%, Excluding Covid-19 Testing-Related Sales >ABT

17. Juli 2025, 11:30 UTC

Ergebnisse

Abbott Labs 2Q Organic Sales Rose 6.9% >ABT

17. Juli 2025, 11:30 UTC

Ergebnisse

Abbott Labs 2Q Adjusted Operating Margin 22.9% >ABT

17. Juli 2025, 11:30 UTC

Ergebnisse

Abbott Labs 2Q Adjusted Gross Margin 57% >ABT

17. Juli 2025, 11:30 UTC

Ergebnisse

Abbott Labs 2Q Organic Sales Growth Up 6.9% >ABT

17. Juli 2025, 11:30 UTC

Ergebnisse

Abbott Labs 2Q Sales $11.14B >ABT

17. Juli 2025, 11:30 UTC

Ergebnisse

Abbott Labs 2Q Net $1.78B >ABT

17. Juli 2025, 11:30 UTC

Ergebnisse

Abbott Labs 2Q Adj EPS $1.26 >ABT

17. Juli 2025, 11:30 UTC

Ergebnisse

Abbott Labs Sees FY Adj EPS $5.10-Adj EPS $5.20 >ABT

17. Juli 2025, 11:30 UTC

Ergebnisse

Abbott Labs 2Q EPS $1.01 >ABT

17. Juli 2025, 09:08 UTC

Heiße Aktien

Stocks to Watch Thursday: TSMC, United Airlines, Sarepta -- WSJ

1. Juli 2025, 18:41 UTC

Akquisitionen, Fusionen, Übernahmen

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

16. Apr. 2025, 15:09 UTC

Market Talk

Abbott Says Tariffs Killed Chances of an Outlook Raise -- Market Talk

16. Apr. 2025, 14:17 UTC

Ergebnisse

Abbott Laboratories Stock Rises as First-Quarter Earnings Surpass Expectations -- Barrons.com

16. Apr. 2025, 11:34 UTC

Ergebnisse

Abbott Labs 1Q Gross Margin of 52.8 % of Sales; Adj Gross Margin of 57.1 % >ABT

16. Apr. 2025, 11:33 UTC

Ergebnisse

Abbott Labs Projects FY25 Adj Operating Margin to Be 23.5% to 24.0% of Sales >ABT

16. Apr. 2025, 11:32 UTC

Ergebnisse

Abbott Labs Backs FY25 Adj EPS $5.05-Adj EPS $5.25 >ABT

16. Apr. 2025, 11:32 UTC

Ergebnisse

Abbott Labs Sees 2Q Adj EPS $1.23-Adj EPS $1.27 >ABT

16. Apr. 2025, 11:31 UTC

Ergebnisse

Abbott Labs Projects FY25 Organic Sales Growth of 7.5% to 8.5% >ABT

16. Apr. 2025, 11:30 UTC

Ergebnisse

Abbott Reaffirms Full-Yr Guidance

16. Apr. 2025, 11:30 UTC

Ergebnisse

Abbott Labs 1Q Organic Sales Growth Up 6.9% >ABT

16. Apr. 2025, 11:30 UTC

Ergebnisse

Abbott Labs 1Q Sales $10.36B >ABT

16. Apr. 2025, 11:30 UTC

Ergebnisse

Abbott Labs 1Q Net $1.33B >ABT

Peer-Vergleich

Kursveränderung

Abbott Laboratories Prognose

Kursziel

By TipRanks

15.54% Vorteil

12-Monats-Prognose

Durchschnitt 145.17 USD  15.54%

Hoch 159 USD

Tief 135 USD

Basierend auf 19 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Abbott Laboratories – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

19 ratings

16

Buy

3

Halten

0

Sell

Technischer Score

By Trading Central

132.82 / 134.43Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Neutral Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

126 / 375 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.